Form 4: Exact Sciences EVP Sells All Shares Post-Abbott Merger

Brian Baranick, EVP of Exact Sciences, reported the disposition of all his common stock and derivative holdings following the company's acquisition by Abbott Laboratories.

Summary

• Brian Baranick, EVP, GM, Precision Oncology of Exact Sciences Corp., reported changes in beneficial ownership.
• The changes occurred on March 23, 2026, following the merger of Exact Sciences into Badger Merger Sub I, Inc., a wholly owned subsidiary of Abbott Laboratories.
• Exact Sciences became a direct, wholly owned subsidiary of Abbott Laboratories.
• Each share of Exact Sciences common stock, with certain exceptions, was converted into the right to receive $105.00 in cash.
• Performance-based restricted stock units (PSUs) vested based on actual achievement as of November 19, 2025, and converted into the right to receive $105.00 in cash per underlying share.
• Restricted stock units (RSUs) granted on or after November 19, 2025, were assumed by Abbott Laboratories as Parent restricted stock units on substantially the same terms and conditions.
• Baranick disposed of 137,195 shares of common stock directly and 795 shares indirectly held in a 401(k) plan.
• Baranick also disposed of 28,063 derivative securities (RSUs).
• Following these transactions, Baranick beneficially owns 0 shares of Exact Sciences common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as a procedural report confirming the successful completion of the Exact Sciences acquisition by Abbott Laboratories, which provided a clear cash exit for shareholders and integration for some equity holders.

Positives

• Exact Sciences shareholders received a cash consideration of $105.00 per share, indicating a successful acquisition for shareholders.
• Certain restricted stock units (RSUs) were assumed by Abbott Laboratories, providing continuity for some employee equity with double-trigger vesting protections.

Negatives

• Exact Sciences ceased to be an independent publicly traded entity.
• The reporting person no longer holds any beneficial ownership in the former Exact Sciences.

Future Outlook

Exact Sciences is now a wholly owned subsidiary of Abbott Laboratories, and its future operations will be integrated within Abbott's structure. Certain restricted stock units assumed by Abbott will vest in four equal annual installments beginning February 25, 2027.

Industry Context

StockSavvy.ai notes that this merger signifies a consolidation within the precision oncology and diagnostics sector, with a major player like Abbott Laboratories expanding its footprint by acquiring Exact Sciences. Such acquisitions often aim to leverage synergies, expand market reach, and integrate complementary technologies, reflecting a broader trend of strategic M&A in the healthcare industry.

Comparison to Industry Standards

• The $105.00 per share cash consideration for Exact Sciences shareholders is a specific deal term and its attractiveness would be benchmarked against the company's historical trading multiples, analyst price targets, and comparable M&A transactions in the diagnostics and oncology space, such as Roche's acquisition of Flatiron Health or Danaher's acquisition of Cepheid.
• The assumption of certain RSUs by Abbott, with double-trigger vesting protections, is a common practice in M&A to retain key talent post-acquisition, aligning with industry standards for employee retention during transitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $105.00 cash per share, realizing value from their investment.
• Employees: Certain employees holding RSUs had their equity assumed by Abbott, providing continuity. Other employees' roles and compensation structures would be subject to Abbott's integration plans.
• Customers/Suppliers: Operations are now under Abbott, potentially leading to changes in product offerings, distribution, and supply chain management.

Next Steps

• Integration of Exact Sciences' operations into Abbott Laboratories.
• Vesting of assumed Parent restricted stock units, with the first installment on February 25, 2027.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Acquisition, Form 4, Insider Transaction, Brian Baranick, Precision Oncology, Restricted Stock Units, Performance Stock Units, Corporate Action